Valeant takes control at Afexa, extends offer; New IMS numbers still show Incivek slowdown;

@FiercePharma: India's Natco inks mAb-sourcing deal with Swiss co., planning to develop 4 biogenerics for India, other Asian markets. More | Follow @FiercePharma

> Valeant Pharmaceuticals ($VRX) ended its Afexa Life Sciences bid with 73.8% of the company, and it's extending its 85-cents-per-share offer through Oct. 27. News

> Vertex Pharmaceuticals ($VRTX) stock dropped on adjusted IMS Health estimates on its hepatitis C drug Incivek, which showed sales hitting a peak in late September and declining slightly thereafter. Item

> India's Natco Pharma inked a deal to source monoclonal antibodies from a Swiss-based company and convert them into four biogeneric drugs for sale in India and other Asian markets. Report

> Abbott Laboratories ($ABT) plans to report third-quarter earnings Wednesday, amid speculation that sales for two of its leading cholesterol drugs are on the decline. Story

> Amgen ($AMGN) tapped President and COO Robert Bradway to join its board, increasing its size to 13 directors. Article

> Novartis ($NVS) launched a ready-to-use formulation of its bone drug Zometa that's easier to use in community settings. Novartis release

> Flamel Technologies set a multiyear supply deal with GlaxoSmithKline ($GSK), agreeing to produce Coreg CR microparticles for the U.K. company. Flamel release

Biotech News

 @FierceBiotech: Third Rock bets $35M on new start-up in risky CNS market, former Lilly R&D head on team. Report | Follow @FierceBiotech

 @JohnCFierce: Is fourth quarter venture funding going to spike after all the moaning and groaning? That would be funny. | Follow @JohnCFierce

 @RyanMFierce: In case you missed it, BBC has neat piece on status of bio batteries that run on water and sugar in the body. Report | Follow @RyanMFierce

 @MaureenFierce: Disgraced South Korean scientist claims to have cloned coyotes, wants to apply tech to endangered species. Story | Follow @MaureenFierce

> MiRagen lands $352M microRNA development pact with Servier. Story

> Google, Kleiner Perkins boost sequencing startup's A round to $33.5M. News

> Third Rock bets $35M on start-up in risky CNS market. Piece

Biotech Research News

> An old drug spurs investigators to think in new ways. Article 

> Stem cell pioneer recognized for drug R&D breakthrough. Report

> Harvard project takes aim at improving drug development odds. Item

Manufacturing News

> GSK site pulls out all stops in plant-investment competition. News

> Senate bill would ease FDA conflict-of-interest rule. Report

And Finally... Researchers identified a species of bacteria prevalent in colon cancer tumors. Report

Suggested Articles

Merck’s Keytruda already boasts an OK in some esophageal cancer patients, but it’s looking to widen its reach in the tough-to-treat disease.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.

The custodial measure came after Chinese customs officials raided Genscript’s businesses for “suspected violations of import and export regulations.”